Basis: Trailing twelve months (TTM). Source: stored company filings and market data; unavailable inputs remain N/A.
Is the gross margin high or low?
The gross margin of 40.82% is in line with its 5-year average of 40.75%, near the high end of its 5-year range (20.96%–47.14%).
0.67% below its 12-month average of 41.09%.
Reported quarterly gross margin; no daily interpolation. Q2 FY2026 (2026-06-30): 40.91%.
GROSS MARGIN
40.82%
GROSS MARGIN AVG TTM
41.09%
GROSS MARGIN AVG 3Y
41.82%
GROSS MARGIN AVG 5Y
40.75%
GROSS MARGIN AVG 10Y
36.49%
GROSS MARGIN AVG 15Y
34.68%
GROSS MARGIN AVG 20Y
N/A
CURRENT VS TTM AVG
-0.67%
CURRENT VS 3Y AVG
-2.40%
CURRENT VS 5Y AVG
+0.17%
CURRENT VS 10Y AVG
+11.86%
CURRENT VS 15Y AVG
+17.72%
CURRENT VS 20Y AVG
N/A
SECTOR MEDIAN · HEALTHCARE
41.38%
median of 863 covered companies
CURRENT VS SECTOR MEDIAN
-1.35%
vs the sector median at left
Market Cap
$470.65M
Gross Margin
87.96%
TTM Avg
85.84%
3Y Avg
84.92%
5Y Avg
81.46%
Market Cap
$472.88M
Gross Margin
33.94%
TTM Avg
26.16%
3Y Avg
30.65%
5Y Avg
37.85%
Market Cap
$469.47M
Gross Margin
0.00%
TTM Avg
0.00%
3Y Avg
25.00%
5Y Avg
20.00%
Market Cap
$473.89M
Gross Margin
0.00%
TTM Avg
0.00%
3Y Avg
0.00%
5Y Avg
0.00%
Market Cap
$474.59M
Gross Margin
52.05%
TTM Avg
54.84%
3Y Avg
54.67%
5Y Avg
54.23%
| NAME | MARKET CAP | GROSS MARGIN | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Kamada Ltd. (KMDA) | $471.36M | 40.82% | 41.09% | 41.82% | 40.75% |
| Sight Sciences, Inc. (SGHT)vs › | $470.65M | 87.96% | 85.84% | 84.92% | 81.46% |
| Alpha Teknova, Inc. (TKNO)vs › | $472.88M | 33.94% | 26.16% | 30.65% | 37.85% |
| Contineum Therapeutics, Inc. (CTNM)vs › | $469.47M | 0.00% | 0.00% | 25.00% | 20.00% |
| Bright Minds Biosciences Inc. (DRUG)vs › | $473.89M | 0.00% | 0.00% | 0.00% | 0.00% |
| Cerus Corporation (CERS)vs › | $474.59M | 52.05% | 54.84% | 54.67% | 54.23% |
| Arvinas, Inc. (ARVN)vs › | $475.19M | 96.43% | 99.01% | 99.50% | 99.67% |
| NRC Health (NRC)vs › | $455.92M | 56.33% | 58.27% | 60.30% | 61.48% |
| Evolus, Inc. (EOLS)vs › | $487.52M | 66.25% | 66.66% | 65.82% | 64.54% |
| Puma Biotechnology, Inc. (PBYI)vs › | $488.38M | 74.83% | 73.30% | 73.96% | 75.53% |
Gross Margin
40.8%
(Revenue - COGS) / Revenue
Gross Margin = Gross Profit / Revenue
Gross margin is the percentage of revenue remaining after the cost of goods sold, reflecting core product profitability.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | GROSS MARGIN |
|---|---|
| 2026-06-30 | 40.91% |
| 2026-03-31 | 42.25% |
| 2025-12-31 | 37.98% |
| 2025-09-30 | 42.04% |
| 2025-06-30 | 42.30% |
| 2025-03-31 | 47.14% |
| 2024-12-31 | 43.66% |
| 2024-09-30 | 41.29% |
| 2024-06-30 | 44.62% |
| 2024-03-31 | 44.39% |
| 2023-12-31 | 39.56% |
| 2023-09-30 | 39.02% |
| 2023-06-30 | 38.55% |
| 2023-03-31 | 38.55% |
| 2022-12-31 | 33.65% |
| 2022-09-30 | 39.95% |
| 2022-06-30 | 30.69% |
| 2022-03-31 | 40.23% |
| 2021-12-31 | 20.96% |
| 2021-09-30 | 24.88% |
| 2021-06-30 | 37.43% |
| 2021-03-31 | 35.87% |
| 2020-12-31 | 32.23% |
| 2020-09-30 | 41.96% |
| 2020-06-30 | 33.59% |
| 2020-03-31 | 34.40% |
| 2019-12-31 | 37.69% |
| 2019-09-30 | 38.90% |
| 2019-06-30 | 38.58% |
| 2019-03-31 | 41.74% |
| 2018-12-31 | 44.09% |
| 2018-09-30 | 16.82% |
| 2018-06-30 | 31.53% |
| 2018-03-31 | 40.23% |
| 2017-12-31 | 32.57% |
| 2017-09-30 | 28.14% |
| 2017-06-30 | 35.98% |
| 2017-03-31 | 19.73% |
| 2016-12-31 | 20.48% |
| 2016-09-30 | 32.40% |
| 2016-06-30 | 29.52% |
| 2016-03-31 | 32.28% |
| 2015-12-31 | 31.95% |
| 2015-09-30 | 23.08% |
| 2015-06-30 | 18.91% |
| 2015-03-31 | 4.39% |
| 2014-12-31 | 31.20% |
| 2014-09-30 | 25.51% |
| 2014-06-30 | -0.42% |
| 2014-03-31 | 24.74% |
| 2013-12-31 | 36.29% |
| 2013-09-30 | 33.90% |
| 2013-06-30 | 46.05% |
| 2013-03-31 | 33.30% |
| 2012-12-31 | 37.35% |
| 2012-09-30 | 32.28% |
| 2012-06-30 | 23.85% |
